Vitamin E, the most important fat-soluble antioxidant in humans, has been reported to be lower in individuals with epilepsy and may be beneficial when used as add-on therapy to AEDs. The study, therefore, aimed to measure the corrected serum vitamin E levels in Nigerian children and adolescents with epilepsy and explore the possible relationship with some clinical characteristics of subjects with epilepsy. The study was cross-sectional in design and conducted over 4 months between February to May, 2017 in 80 subjects with epilepsy aged 3 months to 18 years attending the Paediatric Neurology clinic of Lagos University Teaching Hospital; and 80 age- and sex-matched apparently healthy controls. Serum vitamin E was assayed using reversed-phase high performance liquid chromatography, while cholesterol was assayed spectrophotometrically. Serum vitamin E/cholesterol ratio was then calculated as a more accurate index of vitamin E status. Fifty-nine (73.8%) subjects with epilepsy had generalised seizures, 19 (23.7%) had partial seizures, and 2 (2.5%) had epileptic spasms. 3 (3.6%) subjects with epilepsy had a probable genetic cause, 34 (42.5%) had a structural/metabolic cause, while aetiology was unknown in 43 (53.9%). Seizure severity was classified as mild, moderate and severe in 48 (60.0%), 25 (31.2%) and 7 (8.8%) subjects respectively. Sixty-nine (86.3%) children/adolescents with epilepsy were on monotherapy comprising sodium valproate in 41 (51.3%), carbamazepine in 25 (31.3%) and clonazepam or lamotrigine in 3 (3.7%) subjects, while 11 (13.7%) were on polytherapy.